Skip to main content
Clinical Trials/NCT05447351
NCT05447351
Not yet recruiting
Not Applicable

Effects of Personalized Dietary and Lifestyle Treatments on the Reduction of Cardiovascular and Metabolic Risk in Overweight and Obese Patients

University of Bari1 site in 1 country200 target enrollmentJanuary 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Overweight and Obesity
Sponsor
University of Bari
Enrollment
200
Locations
1
Primary Endpoint
Effects of treatments on Body Mass Index and waist circumference
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

Obesity and overweight are noncommunicable diseases with increasing incidence in children, adolescents and adults. In 2016, more than 1.9 billion adults aged 18 and over were overweight and over 650 million were obese (WHO). In the EU-27 (Eurostat data), 45.7% of women and 60.2% of men were overweight, while 16.3% and 16.8%, respectively, were obese. The growing incidence of overweight and obesity generate worldwide increasing incidence of related conditions as cardiovascular diseases, diabetes, metabolic disorders, and cancer, with relevant socio-economical (increase in health costs, increase in disabilities) and environmental consequences (unsustainability of food models, increase in ecological footprint, worsening of climate changes). A transformation of food systems and individual behaviours are necessary to improve the quality of life and the sustainability of lifestyle, which should be oriented at preventing o treating overweight and obesity.

Detailed Description

The study is aimed to measure the beneficial effects of specific dietary models (i.e., Mediterranean Diet) and healthy lifestyle (i.e., controlled physical activity) in reducing body/organ fat accumulation and in the improvement of metabolic health. A comprehensive and combined analysis of these effects (mainly following personalized strategies and close follow-up) on pathogenic mechanisms affecting cardiovascular and metabolic risk, pro-inflammatory status and intestinal permeability in the medium-long term is still lacking. During the study, overweight/obese subjects (i.e. Body Mass Index equal or higher to 25Kg/m2) will be assessed at basal and monitored during a 24 months follow-up

Registry
clinicaltrials.gov
Start Date
January 2023
End Date
June 2025
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
University of Bari
Responsible Party
Principal Investigator
Principal Investigator

piero portincasa

Professor, MD

University of Bari

Eligibility Criteria

Inclusion Criteria

  • overweight or obese patients
  • patients who able to sign informed consent

Exclusion Criteria

  • failure to sign informed consent;
  • inclusion in other research protocols
  • Normal weight patients

Outcomes

Primary Outcomes

Effects of treatments on Body Mass Index and waist circumference

Time Frame: 24 months

waist circumference will be measured and expressed in cm. weight and height will be combined to report BMI in kg/m\^2. Measurements will be taken at enrollment and during follow-up.

Effects of treatments on visceral fat

Time Frame: 24 months

Measurement of visceral fat by ultrasonography (expressed in mm) will be performed at baseline and during follow-up

Secondary Outcomes

  • Change in metabolic indices and in hormones involved in the regulation of glucose metabolism(24 months)
  • Change in hormones involved in nutrient sensing(24 months)
  • Effects of microbiota and metabolome(24 months)
  • Effects on intestinal permeability(24 months)

Study Sites (1)

Loading locations...

Similar Trials